AA
ANIP icon

ALPS Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

ALPS Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$590K Buy
7,125
+95
+1% +$7.62K ﹤0.01% 906
2026
Q1 		$541K Buy
+7,030
New +$549K ﹤0.01% 697
2016
Q1 		– Sell
-9,381
Closed -$423K – 640
2015
Q4 		$423K Hold
9,381
– – ﹤0.01% 584
2015
Q3 		$371K Buy
9,381
+954
+11% +$54.3K ﹤0.01% 637
2015
Q2 		$523K Buy
8,427
+131
+2% +$7.8K ﹤0.01% 451
2015
Q1 		$519K Buy
+8,296
New +$505K ﹤0.01% 474

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's ANIP Position: Q2 2026 in Review

ALPS Advisors increased its ANI Pharmaceuticals (ANIP) stake by 1.4% in Q2 2026, buying an estimated $7.62K and bringing the position to 7,125 shares worth $590K. The position accounts for ﹤0.01% of the portfolio, ranked #906.

ALPS Advisors first reported a position in ANIP in Q1 2015 and has held it in 6 quarters since. 308 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • ALPS Advisors held 7,125 shares of ANI Pharmaceuticals worth $590K as of Q2 2026.
  • ALPS Advisors bought 95 ANI Pharmaceuticals shares in Q2 2026, an estimated $7.62K.
  • ANI Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #906 holding.
  • ALPS Advisors first reported a position in ANI Pharmaceuticals in Q1 2015 and has held it in 6 quarters since.
  • 308 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.